Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 211

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

CD70, a novel target of CAR T-cell therapy for gliomas

Open access
Jin, Linchun, Ge, Haitao, Long, Yu, Yang, Changlin, Chang, Yifan (Emily), Mu, Luyan, Sayour, Elias J, De Leon, Gabriel, Wang, Qiong J, Yang, James C, Kubilis, Paul S, Bao, Hongbo, Xia, Songsong, Lu, Dunyue, Kong, Yingjun, Hu, Li, Shang, Yujiao, Jiang, Chencheng, Nie, Jing, Li, Shimin, Gu, Yunhe, Sun, Jiahang, Mitchell, Duane A, Lin, Zhiguo, Huang, Jianping · 2018 · Neuro-Oncology

Abstract

Background: Cancer immunotherapy represents a promising treatment approach for malignant gliomas but is hampered by the limited number of ubiquitously expressed tumor antigens and the profoundly immunosuppressive tumor microenvironment. We identified cluster of differentiation (CD)70 as a novel immunosuppressive ligand and glioma target. Methods: Normal tissues derived from 52 different organs and primary and recurrent low-grade gliomas (LGGs) and glioblastomas (GBMs) were thoroughly evaluated for CD70 gene and protein expression. The association between CD70 and patients' overall survival and its impact on T-cell death was also evaluated. Human and mouse CD70-specific chimeric antigen receptors (CARs) were tested respectively against human primary GBMs and murine glioma lines. The antitumor efficacies of these CARs were also examined in orthotopic xenograft and syngeneic models. Results: CD70 was not detected in peripheral and brain normal tissues but was constitutively overexpressed by isocitrate dehydrogenase (IDH) wild-type primary LGGs and GBMs in the mesenchymal subgroup and recurrent tumors. CD70 was also associated with poor survival in these subgroups, which may link to its direct involvement in glioma chemokine productions and selective induction of CD8+ T-cell death. To explore the potential for therapeutic targeting of this newly identified immunosuppressive axis in GBM tumors, we demonstrate that both human and mouse CD70-specific CAR T cells recognize primary CD70+ GBM tumors in vitro and mediate the regression of established GBM in xenograft and syngeneic models without illicit effect. Conclusion: These studies identify a previously uncharacterized and ubiquitously expressed immunosuppressive ligand CD70 in GBMs that also holds potential for serving as a novel CAR target for cancer immunotherapy in gliomas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/nox116

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 211

Metadata

Authors
Jin, L., Ge, H., Long, Y., Yang, C., Chang, Y. (., Mu, L., Sayour, E. J., De Leon, G., Wang, Q. J., Yang, J. C., Kubilis, P. S., Bao, H., Xia, S., Lu, D., Kong, Y., Hu, L., Shang, Y., Jiang, C., Nie, J., Li, S., Gu, Y., Sun, J., Mitchell, D. A., Lin, Z., & Huang, J.
Venue
Neuro-Oncology
Published
2017-06-23
Volume
20
Issue
1
Pages
55-65
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2685700956
Cited by
211
References
5
FWCI
5.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD70, a novel target of CAR T-cell therapy for gliomas. https://app.cochat.ai/papers/10.1093/neuonc/nox116
The paper
Jin, L., Ge, H., Long, Y., Yang, C., Chang, Y. (., Mu, L., Sayour, E. J., De Leon, G., Wang, Q. J., Yang, J. C., Kubilis, P. S., Bao, H., Xia, S., Lu, D., Kong, Y., Hu, L., Shang, Y., Jiang, C., Nie, J., . . . Huang, J. (2018). CD70, a novel target of CAR T-cell therapy for gliomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/nox116

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.